Business Description
Mersana Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US59045L1061
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.22 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 0.91 | |||||
Debt-to-EBITDA | -0.2 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -5.23 | |||||
Beneish M-Score | -2.99 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 190 | |||||
3-Year EBITDA Growth Rate | -0.5 | |||||
3-Year EPS without NRI Growth Rate | 0.6 | |||||
3-Year FCF Growth Rate | -6.4 | |||||
3-Year Book Growth Rate | -54.8 | |||||
Future 3-5Y Total Revenue Growth Rate | -3.45 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.53 | |||||
9-Day RSI | 47.19 | |||||
14-Day RSI | 44.33 | |||||
6-1 Month Momentum % | 215.38 | |||||
12-1 Month Momentum % | -40.96 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.36 | |||||
Quick Ratio | 3.36 | |||||
Cash Ratio | 3.29 | |||||
Days Sales Outstanding | 297.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.6 | |||||
Shareholder Yield % | -21.14 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -463.86 | |||||
Net Margin % | -465.8 | |||||
FCF Margin % | -464.66 | |||||
ROE % | -256.03 | |||||
ROA % | -60 | |||||
ROIC % | -388.07 | |||||
ROC (Joel Greenblatt) % | -1272.2 | |||||
ROCE % | -79.88 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 10.81 | |||||
PB Ratio | 11.24 | |||||
Price-to-Tangible-Book | 11.16 | |||||
EV-to-EBIT | -1.44 | |||||
EV-to-EBITDA | -1.45 | |||||
EV-to-Revenue | 6.54 | |||||
EV-to-Forward-Revenue | 45.18 | |||||
EV-to-FCF | -1.5 | |||||
Price-to-Net-Current-Asset-Value | 16.45 | |||||
Price-to-Net-Cash | 20.84 | |||||
Earnings Yield (Greenblatt) % | -69.41 | |||||
FCF Yield % | -41.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Mersana Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 34.147 | ||
EPS (TTM) (€) | -1.395 | ||
Beta | -1.7 | ||
Volatility % | 165.63 | ||
14-Day RSI | 44.33 | ||
14-Day ATR (€) | 0.17209 | ||
20-Day SMA (€) | 3.1345 | ||
12-1 Month Momentum % | -40.96 | ||
52-Week Range (€) | 0.9416 - 9.238 | ||
Shares Outstanding (Mil) | 122.36 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Mersana Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Mersana Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Mersana Therapeutics Inc Frequently Asked Questions
What is Mersana Therapeutics Inc(STU:0M4)'s stock price today?
When is next earnings date of Mersana Therapeutics Inc(STU:0M4)?
Does Mersana Therapeutics Inc(STU:0M4) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |